mardi 7 janvier 2020

Onco Actu du 7 janvier 2020


1. BIOLOGIE



Cell ‘hands’ to unlock doors in health research, drug design, and bioengineering [Imperial College London]











Brain Cancer Cells Hijack Gene “On Switches” to Drive Tumor Growth [NCI]











Scientists map cancer-related proteins in unprecedented detail [Institute of Cancer Research]











2.13 ETIOLOGIE - NDMA



Carcinogen in Heartburn Drug May Build in Storage, Lab Finds [Bloomberg]










3.1 PRÉVENTION - TABAC



UK tobacco shares rise on U.S. e-cigarette ban exemptions [Reuters]











3.1.1 PRÉVENTION - TABAC - E-CIGS



What if a Vaping Tax Encouraged Cigarette Smoking? [NY Times]










3.3 PRÉVENTION - VACCINS



Broadest ever therapeutic HPV vaccine to be tested in clinical trial [The Guardian]










Even a Single Dose of HPV Vaccine May Provide Protection [NY Times]











3.4.1 CHIMIOPRÉVENTION - ASPIRINE



Aspirin appears to curb colorectal cancer recurrence and tumor growth, study finds [City of Hope]











4.15 DÉP., DIAG. & PRONO. - IMAGERIE



New imaging system and artificial intelligence algorithm accurately identify brain tumors [Neuroscience News]











4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS



Illumina scraps $1.2B PacBio takeover amid regulatory pushback [Biopharma Dive]











Illumina's $1.2B buyout dies amid FTC 'monopolist' accusation [EndPoints]











5.10 TRAITEMENTS - ESSAIS



Complex innovative trials: Authors call for new guideline adoption to get medicines to patients faster [Cancer Research UK]











5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS



BeiGene bags option on Leap cancer drug, requests PD-1 combination trial [Fierce Biotech]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



A new perspective in cancer immunotherapy: PD-1 on myeloid cells takes center stage in orchestrating immune checkpoint blockade [Science Immunology]











A new strategy for boosting PD-1 blockers in melanoma [Fierce Biotech]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery [Cellectis]











5.12.4 IMMUNOTHÉRAPIES - ESSAIS



Pfizer, Merck KGaA's Bavencio posts first-in-class bladder cancer win [Fierce Pharma]










Pfizer, Merck KGaA show immunotherapy's survival benefit in bladder cancer [Biopharma Dive]











BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma [Pfizer]











Merck KGaA, Pfizer's Bavencio set to seal bladder cancer approval after confirmatory trial scores [EndPoints]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Merck's PD-1 star Keytruda flunks a key survival endpoint in SCLC — cue the unfavorable Tecentriq comparisons [EndPoints]










Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Treatment for Extensive Stage Small Cell Lung Cancer [Merck]











5.2 PHARMA



Drug developers take fresh aim at 'guided-missile' cancer drugs [Reuters]










5.2.1 PHARMA - PARTENARIATS



KRAS craze sees Merck put $2.5B biobucks down for Taiho, Astex licensing deal [Fierce Biotech]










Merck Ramps Up KRAS Chase Through Licensing Deal With Taiho, Astex [Xconomy]











Merck adds to lung cancer wall with Otsuka deal [Biopharma Dive]











Merck Establishes Strategic Oncology Collaboration with Taiho and Astex [Merck]











Merck dives deeper into KRAS, teaming up with Taiho, Astex to develop small molecule drugs [EndPoints]











5.2.6 PHARMA - BIOTECH



In a rush? A year after exiting stealth mode, Black Diamond guns for IPO [Fierce Biotech]











Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic [Xconomy]











The first biotech IPO of the new decade has landed — and of course it's another cancer drug developer [EndPoints]











5.3 TRAITEMENTS - FDA, EMA, NICE...



FDA rushed to approve new drugs in 2019, sometimes way ahead of schedule. Could that be dangerous? [EndPoints]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



FDA Approves New Treatment for HER2-positive Breast Cancer [Cancer Research Catalyst]











6.10.1 POLITIQUES (USA)



Washington took a decade to approve an obscure drug-pricing bill. That’s a bad omen for more ambitious reforms [STAT]











6.4 MÉDICO-ÉCO



More than a third of U.S. healthcare costs go to bureaucracy [Reuters]











6.6 PUBLICATIONS



Who Is Competing to Own Researcher Identity? [The Scholarly Kitchen]











6.9 CONTROVERSES



`No progress in cancer care? Really? [Dr. Len]